C12N2310/319 - CPC Classification Index

#1

20250257351

2025-08-14

REVERSIR TM COMPOUNDS

#2

20240229010

2024-07-11

TUNING CRISPR/CAS9 ACTIVITY WITH CHEMICALLY MODIFIED NUCLEOTIDE SUBSTITUTIONS

#3

20220259589

2022-08-18

REVERSIR™ compounds

#4

20220186213

2022-06-16

DIRECT OLIGONUCLEOTIDE SYNTHESIS ON CELLS AND BIOMOLECULES

#5

20220127604

2022-04-28

REVERSIR TM COMPOUNDS

#6

20210198661

2021-07-01

Methods for extending polynucleotides

#7

20210009994

2021-01-14

Direct oligonucleotide synthesis on cells and biomolecules

#8

20190376062

2019-12-12

siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAI, and stabilized forms thereof

#9

20190309295

2019-10-10

Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene

#10

20190185844

2019-06-20

Tuning CRISPR/Cas9 activity with chemically modified nucleotide substitutions

#11

20190040385

2019-02-07

Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof

#12

20180305696

2018-10-25

METHODS AND COMPOSITIONS FOR PREVENTING ISCHEMIA REPERFUSION INJURY IN ORGANS

#13

20180265869

2018-09-20

Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage (3dT)

#14

20180057815

2018-03-01

siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof

#15

20180044671

2018-02-15

DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO P53 AND METHODS OF USE THEREOF

#16

20180010125

2018-01-11

Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof

#17

20170335327

2017-11-23

Methods and compositions for preventing ischemia reperfusion injury in organs

#18

20170081665

2017-03-23

METHODS AND COMPOSITIONS FOR PREVENTING ISCHEMIA REPERFUSION INJURY IN ORGANS

#19

20160355805

2016-12-08

Double stranded oligonucleotide compounds comprising positional modifications

#20

20160230170

2016-08-11

siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAI, and stabilized forms thereof

#21

20160076031

2016-03-17

Phosphorous-linked oligomeric compounds and their use in gene modulation

#22

20160068837

2016-03-10

Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage

#23

20150344886

2015-12-03

RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis

#24

20150267194

2015-09-24

Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof

#25

20150203845

2015-07-23

Double-stranded oligonucleotide molecules to P53 and methods of use thereof

#26

20140357696

2014-12-04

RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis

#27

20140273216

2014-09-18

Synthetic lariat RNA for RNA interference

#28

20140094501

2014-04-03

SiRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof

#29

20130244327

2013-09-19

RNAi sequence-independent modification formats, and stabilized forms thereof

#30

20120322848

2012-12-20

LNA OLIGONUCLEOTIDES AND THE TREATMENT OF CANCER

#31

20120171170

2012-07-05

TREATMENT OF COLLAGEN GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A COLLAGEN GENE

#32

20110257248

2011-10-20

RNAi-related inhibition of TNFα signaling pathway for treatment of ocular angiogenesis

#33

20110190376

2011-08-04

RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA

#34

20110171209

2011-07-14

Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9

#35

20110112168

2011-05-12

Double-stranded RNA directed to CASP2 and methods of use thereof

#36

20110105591

2011-05-05

siRNA compounds for inhibiting NRF2

#37

20100292301

2010-11-18

NOVEL SIRNA STRUCTURES

#38

20100267811

2010-10-21

RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS

#39

20100222414

2010-09-02

siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof

#40

20100190837

2010-07-29

5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom

#41

20100035976

2010-02-11

Method of treating a cancer by administering A 2′,5′-oligoadenylate analog

#42

20100009451

2010-01-14

COMPOSITIONS AND METHODS FOR SPECIFICALLY SILENCING A TARGET NUCLEIC ACID

#43

20090197332

2009-08-06

Modified short interfering RNA

#44

20090181914

2009-07-16

LNA oligonucleotides and the treatment of cancer

#45

20090036397

2009-02-05

RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA

#46

20090036396

2009-02-05

RNAi-RELATED INHIBITION OF TNFalpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS

#47

20060154888

2006-07-13

LNA oligonucleotides and the treatment of cancer

#48

20060025374

2006-02-02

Oligoribonucleotide derivatives for specific inhibition of gene expression

#49

20050261235

2005-11-24

2′, 5′-oligoadenylate analogs

#50

20050233342

2005-10-20

Methods of preventing off-target gene silencing

#51

20050042647

2005-02-24

Phosphorous-linked oligomeric compounds and their use in gene modulation